Abstract
Background This prospective observational study employed resting-state functional MRI (rs-fMRI) to investigate network-level disturbances associated with neurocognitive function (NCF) changes in patients with gliomas following radiation therapy (RT).
Methods Adult patients with either IDH-wildtype or IDH-mutant gliomas underwent computerized NCF testing and rs-fMRI before and 6 months after RT. NCF changes were quantified by the percent change in age-normalized composite scores from baseline (ΔNCFcomp). rs-fMRI data underwent seed-based functional connectivity (FC) analysis. Whole-brain connectivity regression analysis assessed the association between network FC changes and NCF changes, using a split-sample approach with a 26-patient training set and a 6-patient validation set, iterated 200 times. Permutation tests evaluated the significance of network selection.
Results Between September 2020 and December 2023, 43 patients were enrolled, with 32 completing both initial and follow-up evaluations. The mean ΔNCFcomp was 2.9% (SD: 13.7%), with 38% experiencing a decline. Intra-hemispheric FC remained similar between ipsilateral and contralateral hemispheres for most patients at both time points. FC changes accounted for a moderate amount of variance in NCF changes (mean R2: 0.301, SD: 0.249), with intra-network FC of the Parietal Memory Network (PMN-PMN, P=0.001) and inter-network FC between the PMN and the Visual Network (PMN-VN, P=0.002) as the most significant factors. Similar findings were obtained by sensitivity analyses using only the FC data from the hemisphere contralateral to the tumor.
Conclusions Post-RT rs-fMRI changes significantly predicted NCF decline, highlighting rs-fMRI as a promising imaging biomarker for neurocognitive decline after RT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported in part by the Foundation for Barnes-Jewish Hospital and the Washington University Radiation Oncology Departmental research fund (JH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Washington University in St. Louis gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified clinical data from this prospective clinical trial will be available upon reasonable request to the authors.
